These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2252001)

  • 1. Statistical significance of Veterans Administration Vasodilator Heart Failure Trial results.
    Cohn JN
    Am J Cardiol; 1990 Dec; 66(20):1507-8. PubMed ID: 2252001
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN; Archibald DG; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Francis GS; Flohr KH
    N Engl J Med; 1986 Jun; 314(24):1547-52. PubMed ID: 3520315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasodilator therapy on mortality in chronic congestive heart failure.
    Cohn JN
    Eur Heart J; 1988 Jan; 9 Suppl A():171-3. PubMed ID: 3044793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
    Cohn JN; Archibald DG; Francis GS; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Flohr KH
    Circulation; 1987 May; 75(5 Pt 2):IV49-54. PubMed ID: 3552302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
    Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI1-4. PubMed ID: 8500232
    [No Abstract]   [Full Text] [Related]  

  • 7. [Vasodilator agents in the therapeutic arsenal of cardiac insufficiency].
    Lavitola Pde L; Higa SS
    Rev Paul Med; 1986; 104(3):136-40. PubMed ID: 3563266
    [No Abstract]   [Full Text] [Related]  

  • 8. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
    Packer M
    Chest; 1980 Jan; 77(1):7-9. PubMed ID: 7351152
    [No Abstract]   [Full Text] [Related]  

  • 10. [Modern vasodilator medication in refractory cardiac insufficiency].
    Stanciu L; Branea I; Riviş I; Radivoievici A; Mancaş S; Păunescu A
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(2):129-34. PubMed ID: 6139858
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of vasodilator drugs in congestive heart failure.
    Med Lett Drugs Ther; 1978 Oct; 20(20):89-91. PubMed ID: 703684
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G; Carson P; Francis GS; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vasodilator agents in the treatment of heart failure].
    Prati PL; Manfrin M
    G Ital Cardiol; 1978; 8(1):1-11. PubMed ID: 415927
    [No Abstract]   [Full Text] [Related]  

  • 14. Vasodilators in the treatment of congestive heart failure.
    Ciafone RA
    Conn Med; 1983 Oct; 47(10):614-8. PubMed ID: 6414758
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
    Cohn JN
    Drugs; 1994; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
    Goldman S; Johnson G; Cohn JN; Cintron G; Smith R; Francis G
    Circulation; 1993 Jun; 87(6 Suppl):VI24-31. PubMed ID: 8500236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current indications for vasodilator therapy for left ventricular failure.
    Franciosa JA
    Compr Ther; 1985 Mar; 11(3):39-46. PubMed ID: 2983926
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
    Cohn JN
    Herz; 1991 Sep; 16 Spec No 1():267-71. PubMed ID: 1820292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group.
    Wong M; Johnson G; Shabetai R; Hughes V; Bhat G; Lopez B; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI65-70. PubMed ID: 8500242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
    Carson PE; Johnson GR; Dunkman WB; Fletcher RD; Farrell L; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI102-10. PubMed ID: 8500233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.